Merck to Market Xian Janssen's SGLT-2 Diabetes Drug in China

03:24 EDT 13 Jul 2018 | ChinaBio Today

Germany's Merck KGaA will market Xian Janssen's Inovokana® in China. Inovokana, a novel treatment for type 2 diabetes, is a member of the relatively new sodium-glucose co-transporter 2 (SGLT-2) class of oral diabetes treatments. In China, Merck already distributes Glucophage® (metformin hydrochloride) and other diabetes products, while Janssen has no presence in the sector. Approved almost one year ago for China use, Inovokana is the market leader globally among SGLT-2 offerings, though it will be third to market in China. More details....

Stock Symbols: (F: MRK)

Share this with colleagues:

Original Article: Merck to Market Xian Janssen's SGLT-2 Diabetes Drug in China


More From BioPortfolio on "Merck to Market Xian Janssen's SGLT-2 Diabetes Drug in China"

Quick Search


Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...